Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Adcendo is a biotech company that develops antibody-drug conjugates (ADCs) to target cancers with high unmet medical needs.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
AN2 Therapeutics focuses on modern biomedical and drug development expertise to provide transformational medicines.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF).
Orchard Therapeutics is a biotechnology company dedicated to assisting patients through innovative gene therapies.
Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
NexCure offers clinically intense therapies in outpatient, community settings, and other cutting-edge treatments.
OnKure is a clinical-stage biopharma company developing precision medicines targeting validated cancer drivers.
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs.
Terrestrial Bio engages in developing biomedical innovations with a focus on improving access to vaccines.
Nkarta Therapeutics is a developer of cell engineering platform created to build the next generation of cell therapies.
Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.
Candid Therapeutics develops therapies for autoimmune diseases using antibody-based technologies that modulate immune system activity.
TeraPore Technologies is a Cornell University spinout that develops and manufactures high performance filters for protein separations.
Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases.
Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.
Ovid Therapeutic's purpose is to solve intractable medical problems.
RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. RA Capital Management's total known invested capital is $44.2B.
RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.
Recent RA Capital Management portfolio additions include Prelude Therapeutics, Ventus Therapeutics, Terremoto Biosciences, ADCendo, CDR-Life AG. These companies were founded in 2020 or later.